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An a-Si Active Matrix Flat Panel Imager sAMFPId prototype developed in-house has been modified
to function as an in-phantom dosimetry system providing high resolution two-dimensional s2-Dd
data. This Active Matrix Flat Panel Dosimeter sAMFPDd system can be used as a replacement
device for standard in-phantom dosimeters, such as scanning ion chambers in water, or film in solid
water. The initial characterization of the device demonstrates a wide dynamic range sup to 160
cGyd, a stable calibration curve sless than 1.5% variation over 1 yeard, dose rate independence sless
than 1%d, and excellent agreement of output factors with ion chamber measurements for a range of
field sizes sless than 2%d. The device also compares well to film for 2-D planar dose distributions.
It is expected that the AMFPD system will be useful for beam commissioning, algorithm verifica-
tion test data, and routine IMRT quality assurance dosimetry. © 2005 American Association of
Physicists in Medicine. fDOI: 10.1118/1.1855012gKey words: dosimetry, amorphous silicon, active matrix flat panel dosimeter, quality assuranceI. INTRODUCTION
The quality assurance of linear accelerators and treatment
planning systems requires the acquisition of data in three
dimensions. The development of electronic portal imaging
systems has resulted in an increased interest in using such
systems for dosimetric applications to replace 2-D film mea-
surements. CCD cameras with fluorescent screens,1–3 liquid-
filled ion chamber arrays,4 and amorphous silicon flat
panel imagers have been investigated.5–7 These systems have
been applied to transit dosimetry8–11 and pre-treatment field
verification.7,12,13
Previous work by El-Mohri14 involved an examination of
in-phantom dosimetric properties of a prototype active ma-
trix flat panel imager sAMFPId operated in an indirect mode
swith a fluorescent screend and in a direct mode swith no
screen presentd. The detector response was evaluated as a
function of dose, dose rate, and stability of the pixel response
for doses up to approximately 25 cGy. Comparisons were
made to ion chamber measurements in water. The study dem-
onstrated that the AMFPI, when operated in the direct detec-
tion mode, had a response much more similar to the mea-
sured ion chamber data than when operated in an indirect
detection mode. This result suggested that it would be pos-
sible to obtain dose distribution information from an active
matrix flat panel detector sAMFPDd operated in a direct de-
tection mode.
The current work extends that of the previous
investigation14 by modifying an in-house developed AMPFI
device, similar to one used in previous work, for higher dose
applications. The system response was investigated over a
wider range of doses such as those required for commission-
ing and patient dosimetric measurements of static and IMRT
fields. The system was designed specifically to replace film
in water-equivalent phantoms.
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A. System description
The a-Si detector array has 5123512 pixels with a 508
µm pixel pitch, yielding a detector area of approximately
26326 cm2. To increase the dynamic range of the detector,
the image acquisition electronics for the system were modi-
fied from the original AMFPI to incorporate preamplifiers
whose gains were matched to the full pixel charge capacity
of approximately 90 pC at a bias of −5 V applied to the
photodiodes sVbiasd. The AMFPD is operated in the direct
detection mode.14 These changes result in a reduction of the
overall system gain.
B. Operating conditions
The array was mounted in an aluminum support frame
ssee Fig. 1d. During measurements, the system is operated in
the dark and covered with a dark cloth to minimize any am-
bient room light. A 2 cm thick piece of 30330 cm2 solid
water sGammex-RMI 457, Middleton, WId is placed directly
on the array. The weight of additional 40340 cm2 solid wa-
ter pieces was borne by the aluminum support frame in order
to protect the array. This setup results in an air gap of less
than 0.5 mm between the solid water pieces. A 6.5 cm thick
slab of solid water is placed below the detector to provide
adequate backscatter. The system was operated in the radio-
graphic mode in which the pixel data are read out after the
complete dose delivery.
A number of steps are followed to determine the mea-
sured dose with the AMFPD system. Dark frame measure-
ments are made to extract the dark current and individual
pixel offsets using a linear model. The measured dose for an
irradiated frame is determined in two steps. First, the dark
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the measurement to obtain a corrected measurement sMcorrd
at each pixel position:
Mcorri,j = Mrawi,j − Idarki,j · Dt − Oi,j , s1d
where, for a given pixel si , jd ,Mraw is the raw or uncorrected
radiation image, Idark is the dark current, Dt is the frame time
for the dark image, and O is the offset correction. The dose is
calculated from
Di,j = fsGi,j · Mcorri,jd , s2d
where, for each pixel si , jd ,D is the dose, G is the gain cor-
rection, and Mcorr is the corrected measurement sin corrected
ADC unitsd. The function, f , is used to convert from cor-
rected ADC units to dose using a dose calibration curve. The
dose calibration curve is determined from a high tension
spline applied to the measured calibration data. The splined
fit to the data is used as a lookup table to determine the dose
at each pixel position.
Because the pixel gains are sensitive to the charge trap-
ping density, the system is operated in a specific sequence. At
the beginning of each set of measurements, the system is
initialized with a 30330 cm2 flood field for a dose of ap-
proximately 240 cGy. The electronics are moved as far as
possible from the detector so they are not directly exposed.
Prior to the delivery of each measurement field, another 30
330 cm2 flood field sapproximately 80 cGyd is delivered so
that each pixel has approximately the same charge trapping
density prior to the beginning of each measurement. For each
pixel, the gain stability was checked by comparing the flood
field to measurements made with film scorrected to dosed for
the same field size and depth in solid water. Any data from
bad address lines or malfunctioning preamplifier channels
are removed and replaced with values determined from the
FIG. 1. Active Matrix Flat Panel Dosimeter mounted in a support frame and
positioned in solid water phantom.application of a 3 pixel33 pixel median filter. Note that the
Medical Physics, Vol. 32, No. 2, February 2005median filter is only used to correct values for bad pixels;
pixels with a normal response are not smoothed in any way.
C. Device characterization
The AMFPD response was evaluated as a function of the
dose, dose rate, beam energy, and field size. In addition,
measurements of the 6 MV dosimetric calibration curve were
made one year apart to evaluate the long-term stability of the
calibration. All measurements with the AMFPD and film
were made perpendicular to the beam.
Prior to use of the system for dosimetric measurements,
the response of each preamplifier channel was determined by
injecting known charges into each channel. The stability of
the preamplifier calibration was also evaluated over time by
evaluating flood field measurements made over a period of 1
year. To assess the long-term stability, the charge injection
was repeated for a single channel in each preamplifier.
The initial characterization of the AMFPD was performed
on a linear accelerator using 6 MV and 16 MV photon beams
equipped with a 120 leaf multileaf collimator sVarian 21 EX,
Varian Medical Systems, Palo Alto, CAd. Unless explicitly
stated, experiments were conducted at 90 cm SSD, 10 cm
depth, and a dose rate of 320 cGy/min. The linear accelera-
tor was calibrated so that 1 monitor unit sMUd with a 10
310 cm2 jaw field results in a dose of 0.8 cGy on the central
axis at 10 cm depth and 90 cm SSD.
For 6 and 16 MV, a dose characterization curve was mea-
sured for doses ranging from 0.8–160 cGy under the accel-
erator calibration conditions. The curve was measured again
one year later for 6 MV to assess the long-term stability of
the system. The AMPFD response was also measured at 80
cGy s100 MUd for dose rates of 80 to 480 cGy/min in in-
crements of 80 cGy/min s100 to 600 in MU/mind. For this
analysis, the AMFPD response was averaged over a detector
region of 11311 pixels at the center of the field. The depen-
dence of the pixel response on the beam energies of 6 and 16
MV was investigated under the calibration conditions for a
detector region of 636 pixels at the center of the field.
To assess the field size dependence of the system, mea-
surements were made for a 6 MV beam for MLC fields rang-
ing from 333 cm2 to 25325 cm2 at 90 cm SSD and 10 cm
depth. To demonstrate the potential of the system, AMFPD
planar dose distributions were compared to film for a 10
310 cm2, an MLC-shaped static field and a sample IMRT
head and neck field.
The lag and ghosting effects associated with charge trap-
ping at high doses for this device, when operated under simi-
lar conditions as described in this work, have previously
been reported.15
III. RESULTS
Long-term stability was evaluated for the preamplifier
calibration and the system. As noted above, the response
of each preamplifier channel was determined by inject-
ing known charges into each channel. At 1.5 years later, the
response of a single channel for each preamplifier was re-
evaluated using the charge injection method fFig. 2g. The
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than 1.5%. The stability of the dosimetric response of
the system was evaluated by measurement of the dose cali-
bration curve at an initial time point and at 1 year later for 6
MV. The calibration curve, derived using Eq. s1d, was mea-
sured for doses ranging from 0.8 to 160 cGy fFig. 3sadg. The
system response varied by less than 1.5% over that time
fFig. 3sbdg.
FIG. 2. The response for a single channel in each preamplifier is shown at
two time points s1.5 years apartd. The variation in the response at the two
time points was less than 1.5%.
FIG. 3. sad AMFPD dose calibration curve for 6 MV photons at 10
310 cm2 at 10 cm depth at 2 different times measured 1 year apart ssolid
line with squares and circlesd and for 16 MV photons sdashed line with
trianglesd. sbd Percent difference between 6 MV data points and 6 MV and
16 MV values.
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dose, dose rate and field size. A comparison of the calibration
measurements for 6 and 16 MV were found to agree to
within 3%. The dependence of the system on the dose rate
was measured for 6 MV and found to be less than 1% for all
dose rates. To evaluate the dependence of the AMFPD on
field size, the output factor was determined relative to a 10
310 cm2 field for square field sizes ranging from 3
33 cm2 to 25325 cm2 fFig. 4sadg. The AMFPD results
were within 2% of the ion chamber measurements fFig.
4sbdg.
The AMFPD system was developed for measurement of
in-phantom planar dose distributions. Figure 5sad shows a
2-D dosimetric comparison for a 6 MV 10310 cm2 field
measured with film and the AMFPD at 10 cm depth normal-
ized to 100% dose at the central axis of the field. Agreement
is within 2% between the isodose lines sexcept for the pen-
umbra regiond. Figure 5sbd shows a profile extracted from
both images across the center of the field. In addition, an ion
chamber s0.13 cm3 CC13 chamberd profile is shown, mea-
sured under similar conditions sexcept in a water phantomd.
Agreement between the ion chamber and AMPFD data is
within 1% in the majority of the field. Some larger differ-
ences are seen in the penumbra region, where averaging over
the ion chamber volume results in a less accurate dose deter-
16
FIG. 4. sad A comparison of the field size dependence of the output factor for
ion chamber ssquaresd and AMFPD strianglesd measurements in solid water.
sbd The relative difference sin percentd between the ion chamber and AM-
FPD data shown in sad.mination in the penumbra region. Figure 6 shows a com-
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as a “C” with an MLC at depths of 1.5 and 10 cm normalized
at x=−4 cm, y=0 cm. Good agreement is seen for the iso-
dose lines displayed. At 1.5 cm depth, there is a discrepancy
in the 100% isodose curve. At 10 cm depth, there are some
discrepancies seen in the 10% isodose lines.
Finally, a sample SMLC-IMRT field was measured at 5
cm depth. Figure 7 shows a dosimetric comparison of the
film and AMFPD measurements in cGy. The film and AM-
FPD data were converted to dose using the appropriate cali-
bration curves without renormalization. Excellent agreement
was seen for most isodose lines. Small discrepancies be-
tween lines within the field represent differences in dose up
to approximately 5 cGy.
IV. DISCUSSION
A prototype a-Si Active Matrix Flat Panel Imager sAM-
FPId has been successfully modified for use as an in-phantom
2-D dosimetry system, guided by an earlier investigation.14
The resulting Active Matrix Flat Panel Dosimeter sAMFPDd
system has been shown to be useful across a wide range of
delivered doses sup to 160 cGy for an individual irradiationd
Medical Physics, Vol. 32, No. 2, February 2005and maintains a stable calibration over a period of a year.
Further work using the AMFPD for beam commissioning
and IMRT measurements is underway.
The AMFPD response is independent of dose rate, to bet-
ter than ±1%, for dose rates up to 480 cGy/min. The ab-
sence of dose rate dependence is very important for any do-
simetric system, especially for applications involving the
dosimetric verification of IMRT fields where the actual dose
rate at the AMFPD may vary during delivery. The AMFPD
calibration and sensitivity appear to be very stable. While the
original prototype imager system was shown to be stable for
a period of over 2 months,14 the present work indicates that
the calibration curve of the AMFPD varies by less than 1.5%
over a full 12 month period. In addition, output factors, mea-
sured with the AMFPD, agreed to within 2% of ion chamber
measurements, extending the applicability of the device for
commissioning measurements. Finally, the preamplification
coefficients have been stable with time. Therefore, it is not
necessary to recalibrate the preamplifiers before each mea-
surement, although the coefficients are nevertheless moni-
tored on a regular basis.
There are a number of potential issues for the practical
FIG. 5. sad The planar dose distribution comparison for
a 10310 cm2 field at 10 cm depth for film ssolid linesd
and AMFPD sdotted linesd in solid water. Isodose lines
of 100%, 90%, 80%, 50%, 20%, and 10% are shown.
sbd Extracted field profiles across the central axis from
film sdashed-dotted lined and AMFPD sdashed lined are
compared to ion chamber measurements ssolid lined in
water.use of such AMFPD systems which require further investi-
470 Moran et al.: AMFPD for in-phantom dosimetric measurements 470gation. The current method of correcting for pixel-to-pixel
variations requires a specific sequence of AMFPD operation.
Prior to irradiation and measurement of the field of interest,
dark frames are acquired and then a flood field is delivered
and measured. In this calibration process, the dark frames are
FIG. 6. Planar dose distribution comparisons for a shaped field for film
ssolid linesd and AMFPD sdotted linesd at sad 1.5 cm depth for isodose lines
of 100%, 60%, and 10% and sbd 10 cm depth for isodose lines of 100%,
60%, 20%, and 10%. The scale is in 1 cm increments.assumed to be free from residual signal contributions from
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used in this system, such contributions, in the form of ghost-
ing and lag, may affect the accurate determination of dark
frames.15,17 The effects of ghosting and lag on a given mea-
surement can be accentuated for IMRT fields due to the po-
tential range of intensities in a given field. Hence, solutions
must be devised for clinical applications.
When evaluating the dose response outside the field, it
should be noted that the AMFPD over-responds to low-
energy photons due to the atomic number of silicon and other
materials in the system, similar to the over-response seen
with film and diodes.18 The impact of this difference on
IMRT fields depends on the delivery method of the field. A
Monte Carlo evaluation of transmission through the MLC
demonstrated the hardening of photon beams after transport
through a multileaf collimator.19 Depending on the complex-
ity of the IMRT field, leakage can comprise as much as 10%
of the maximum in-field dose.19,20 This leads to a decrease in
the number of low-energy photons reaching the film or AM-
FPD device. For dynamic delivery, it was determined that
there is an increased scatter dose through the curved leaf
tips.19 Therefore, this effect would need to be considered
when evaluating film or AMFPD measurements of such
fields.
Clear advantages of the AMPFD system over film dosim-
etry include the electronic acquisition of dosimetric data and
automatic data processing. In addition, the AMPFD is ideal
for technique comparisons at a single depth because the
alignment of the beam to the detector is known and is con-
stant for multiple measurements. In contrast, film dosimetry
FIG. 7. Planar dose comparison for an SMLC-IMRT field at 5 cm depth for
film ssolidd and AMFPD sdottedd in solid water. Isodose lines of 60, 50, 30,
and 10 cGy are shown. The scale is in 1 cm increments.requires fiducials to determine the position of each film with
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phantom for each measurement. For each experiment, a do-
simetric characteristic response curve must be measured to
account for variations in film processing. The number of
films required for the acquisition of the characteristic curve
can be reduced by using a method with multiple dose levels
per film.21 After data acquisition, each film must be devel-
oped and digitized. Finally, it must be independently regis-
tered with film analysis software and converted to dose for
comparison to calculations or other data. A reliable film do-
simetry program also requires QA of the processor and digi-
tizer.
While the AMFPD was intended specifically to replace
film for measurements at multiple depths in a phantom, some
limited comparisons can be made to commercial AMFPIs
that have been investigated for dosimetry.6,7,22–24 In those
studies, commercial AMFPI systems saS500, Varian Medical
Systems, Palo Alto, CAd were operated in a continuous-
acquisition mode during dose delivery and the response was
then averaged over all frames in order to limit saturation of
the imager pixels.7 When operating in that mode, some loss
of signal occurs due to dead time while the frames are read
out by the acquisition electronics.24
Because AMFPI systems include scintillator material
above the detector, a water-equivalent depth of approxi-
mately 8 mm has been determined experimentally for the
commercial AMFPI aS500 system.7 Models have been de-
veloped to address the effect of the scintillator on EPID re-
sponse. For example, energy deposition in the detector has
been modeled using dose kernels to generate a detector re-
sponse function.6 Another approach models the detector re-
sponse by deconvolving the raw image with s1d a Monte
Carlo-calculated scatter kernel for dose deposition in the
scintillator and s2d an empirically-derived kernel for optical
photon spreading.23 For use with a pencil beam model for
dose calculation, improved agreement between calculations
and EPID response was shown when the portal dose was
calculated in the AMPFI and not in water.7
The role of the AMPFD differs significantly from com-
mercial AMFPIs. The effect of the scintillator as well as the
difficulties in using buildup for gantry-mounted systems sdue
to weight limits on the control armd, limit the application of
current commercial AMFPIs primarily to single plane verifi-
cation such as that required for IMRT pre-treatment QA. As
such, commercial AMFPIs offer a significant time-savings
over current pre-treatment verification methods. The AM-
FPD described in this work is much more similar to a film
dosimetry replacement in solid water, due to the absence of a
fluorescent screen, compared to commercial AMFPIs. The
system has the potential to replace film dosimetry at a time
when many radiation oncology departments are considering
removing film processors because EPIDs are used for all
patient positioning verification.
V. CONCLUSIONS
A prototype a-Si imaging system has been successfullymodified to perform dosimetric measurements in solid water.
Medical Physics, Vol. 32, No. 2, February 2005The active matrix flat panel dosimeter sAMFPDd system de-
scribed in this paper differs from commercial AMFPI portal
imaging systems in a number of respects. The system oper-
ates in direct detection mode, without a fluorescent screen.
The electronics associated with the system have been modi-
fied to give it an increased dynamic range so that up to 160
cGy can be measured in a single integration. The AMFPD is
mounted in a frame and backed with solid water, enabling
in-phantom measurements at multiple depths. The dose cali-
bration curve of the system is stable. Comparisons to ion
chamber and film measurements for sample static-MLC and
IMRT field shapes show the potential of the AMFPD as a
dosimeter.
Future work will characterize, in detail, the use of the
AMFPD for beam commissioning and IMRT quality assur-
ance measurements. With additional effort, it is expected that
the AMFPD will prove to be an essential dosimeter for 3-D
and IMRT dose calculation verification and machine com-
missioning data.
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